CRISPR Therapeutics (CRSP) – Hot New Coverage
-
Mizuho Securities Starts CRISPR Therapeutics (CRSP) at Buy
-
Cantor Starts CRISPR Therapeutics (CRSP) at Overweight, 'A Year of Catalysts Could Bring Money Back into This Gene Editing Play'
-
-
-
-
-
-
-
-
Back to CRSP Stock Lookup